Comparable stake leader
AQR CAPITAL MANAGEMENT LLC
SEC ownership of HAEMONETICS CORP
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000313143.
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
31 Mar 2026
- Public ticker
- HAE on NYSE
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
AQR CAPITAL MANAGEMENT LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
AQR CAPITAL MANAGEMENT LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Mar 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0000313143
- Issuer location
- Boston, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of HAEMONETICS CORP (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
AQR CAPITAL MANAGEMENT LLC
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
31 Mar 2026
13D/G
13F
3/4/5
Lead comparable stake: 6.8%
13D/G row: AQR CAPITAL MANAGEMENT LLC
Showing 1-8 of 50 holder rows.
Quick read
AQR CAPITAL MANAGEMENT LLC leads the comparable SEC ownership view at 6.8%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens AQR CAPITAL MANAGEMENT LLC's linked filing trail.
Comparable ownership
Top 5
AQR CAPITAL MANAGEMENT LLC
6.8%
VANGUARD PORTFOLIO MANAGEMENT LLC
5.6%
VANGUARD CAPITAL MANAGEMENT LLC
5.3%
WELLINGTON MANAGEMENT GROUP LLP
4.6%
T. Rowe Price Investment Manageme...
4.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| AQR CAPITAL MANAGEMENT LLC |
13D/G
13F
Company
|
6.8%
|
$253,522,786
3,163,104 shares
|
$0 | 31 Dec 2025 |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13D/G
13F
Vanguard Portfolio Management · Company
|
5.6%
|
$146,544,172
2,600,145 shares
|
$0 | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
Vanguard Capital Management · Company
|
5.3%
|
$137,846,246
2,445,817 shares
|
$0 | 31 Mar 2026 |
| WELLINGTON MANAGEMENT GROUP LLP |
13D/G
13F
Company
|
4.6%
|
$165,537,761
2,203,351 shares
|
-$36,448,193 | 30 Jun 2025 |
| T. Rowe Price Investment Management, Inc. |
13D/G
13F
Company
|
4.4%
|
$135,949,632
2,195,569 shares
|
$0 | 31 Mar 2025 |
| Capital Research Global Investors |
13D/G
|
3.1%
|
$97,667,840
1,577,323 shares
|
$0 | 31 Mar 2025 |
| Charles J. Dockendorff |
3/4/5
Director
|
0.05%
|
$1,868,308
25,041 shares
|
— | 24 Jul 2025 |
| Robert E. Abernathy |
3/4/5
Director
|
0.05%
|
$1,863,832
24,981 shares
|
— | 24 Jul 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$98,784.
Buys
$98,784
Insiders: 1
Sells
$0
Insiders: 0
Net
+$98,784
Shares: +1,400
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 1,400
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 1,400 | 0 | $98,784 | $0 | +$98,784 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 23 reporting-owner rows connected to HAEMONETICS CORP. Open a relationship link for the CIK-to-CIK filing trail.
Rows
23
Largest Forms 3/4/5 holder
Christopher Simon
Net 12M change
+$98,784
Latest report
05 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Christopher Simon | President & CEO, Director | $25,063,517 | Median | 15 May 2026 | ||
| Michelle L. Basil | EVP and General Counsel | $3,879,202 | Median | 15 May 2026 | ||
| James Darecca | EVP, Chief Financial Officer | $3,068,463 | Median | 15 May 2026 | ||
| Josep Llorens | EVP, Global Manufacturing | $2,961,886 | Mixed | 28 May 2024 | ||
| William P. Mr. Burke | EVP, Chief Financial Officer | $2,616,839 | Mixed | 23 Aug 2021 | ||
| Laurie A. Miller | SVP, Human Resources | $2,310,027 | Median | 05 Jun 2026 | ||
| Roy Galvin | EVP, Chief Commercial Officer | $2,247,749 | Median | 15 May 2026 | ||
| Anila Lingamneni | EVP, Chief Technology Officer | $1,919,790 | Filing P/S | 11 Jul 2024 | ||
| Charles J. Dockendorff | Director | $1,868,308 | Mixed | 24 Jul 2025 | ||
| Robert E. Abernathy | Director | $1,863,832 | Mixed | 24 Jul 2025 | ||
| Frank Chan | EVP, Chief Operating Officer | $1,856,272 | Median | 15 May 2026 | ||
| Mark W. Kroll | Director | $1,746,853 | +$98,784 | +6% | Filing P/S | 10 Nov 2025 |
| Catherine M. Burzik | Director | $1,688,493 | Mixed | 05 Aug 2022 | ||
| Stewart W. Strong | President, Global Hospital | $1,658,565 | Filing P/S | 26 Jul 2024 | ||
| Chad M. Nikel | President, Global Plasma & BC | $1,497,657 | Mixed | 06 Aug 2021 | ||
| Ellen M. Zane | Director | $1,445,419 | Mixed | 24 Jul 2025 | ||
| Claire Pomeroy | Director | $1,258,819 | Mixed | 24 Jul 2025 | ||
| Michael J. Coyle. | Director | $1,148,546 | Mixed | 24 Jul 2025 | ||
| Lloyd E. Johnson | Director | $964,931 | Mixed | 24 Jul 2025 | ||
| Diane M. Bryant | Director | $531,670 | Mixed | 24 Jul 2025 |
Recent insider transactions for HAEMONETICS CORP
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Farris Maryanne Maunsell | HAE | Common Stock | Tax liability | -3.98% | -259 | 6,242 | 05 Jun 2026 | Direct | ||
| Laurie A. Miller | HAE | Common Stock | Tax liability | -0.76% | -313 | 40,987 | 05 Jun 2026 | Direct | ||
| Michelle L. Basil | HAE | Common Stock | Award | 70.4% | 28,424 | 68,829 | 15 May 2026 | Direct | ||
| Michelle L. Basil | HAE | Common Stock | Tax liability | -6.72% | -2,913 | 40,405 | 15 May 2026 | Direct | ||
| Frank Chan | HAE | Common Stock | Award | 509.8% | 27,535 | 32,936 | 15 May 2026 | Direct | ||
| Frank Chan | HAE | Common Stock | Tax liability | -9.18% | -546 | 5,401 | 15 May 2026 | Direct | ||
| James Darecca | HAE | Common Stock | Award | 116.6% | 29,312 | 54,444 | 15 May 2026 | Direct | ||
| James Darecca | HAE | Common Stock | Tax liability | -9.06% | -2,505 | 25,132 | 15 May 2026 | Direct | ||
| Farris Maryanne Maunsell | HAE | Common Stock | Award | 51.9% | 2,220 | 6,501 | 15 May 2026 | Direct | ||
| Farris Maryanne Maunsell | HAE | Common Stock | Tax liability | -4.4% | -197 | 4,281 | 15 May 2026 | Direct | ||
| Roy Galvin | HAE | Common Stock | Award | 223% | 27,535 | 39,882 | 15 May 2026 | Direct | ||
| Roy Galvin | HAE | Common Stock | Tax liability | -6.65% | -879 | 12,347 | 15 May 2026 | Direct | ||
| Laurie A. Miller | HAE | Common Stock | Award | 47.6% | 13,323 | 41,300 | 15 May 2026 | Direct | ||
| Laurie A. Miller | HAE | Common Stock | Tax liability | -3.28% | -948 | 27,977 | 15 May 2026 | Direct | ||
| Christopher Simon | HAE | Common Stock | Award | 21.4% | 78,344 | 444,704 | 15 May 2026 | Direct | ||
| Christopher Simon | HAE | Common Stock | Tax liability | -2.57% | -9,681 | 366,360 | 15 May 2026 | Direct | ||
| James Darecca | HAE | Common Stock | Tax liability | -2.32% | -655 | 27,637 | 01 May 2026 | Direct | ||
| Mark W. Kroll | HAE | Common Stock | Purchase | 5.99% | $98,784 | $70.56 | 1,400 | 24,757 | 10 Nov 2025 | Direct |
| Roy Galvin | HAE | Common Stock | Tax liability | -1.12% | -145 | 12,811 | 31 Oct 2025 | Direct | ||
| Laurie A. Miller | HAE | Common Stock | Tax liability | -0.82% | -238 | 28,925 | 17 Sep 2025 | Direct | ||
| Ellen M. Zane | HAE | Common Stock | Award | 16.2% | 2,693 | 19,373 | 24 Jul 2025 | Direct | ||
| Claire Pomeroy | HAE | Common Stock | Award | 19% | 2,693 | 16,872 | 24 Jul 2025 | Direct | ||
| Mark W. Kroll | HAE | Common Stock | Award | 13% | 2,693 | 23,357 | 24 Jul 2025 | Direct | ||
| Lloyd Emerson Johnson | HAE | Common Stock | Award | 26.3% | 2,693 | 12,933 | 24 Jul 2025 | Direct | ||
| Charles J. Dockendorff | HAE | Common Stock | Award | 60.8% | 2,693 | 7,126 | 24 Jul 2025 | Direct | ||
| Michael J. Coyle | HAE | Common Stock | Award | 21.2% | 2,693 | 15,394 | 24 Jul 2025 | Direct | ||
| Diane M. Bryant | HAE | Common Stock | Award | 60.8% | 2,693 | 7,126 | 24 Jul 2025 | Direct | ||
| Robert E. Abernathy | HAE | Common Stock | Award | 12.1% | 2,693 | 24,981 | 24 Jul 2025 | Direct |
* marks a reported price that did not pass the local price check.